

Paulo Cury Rezende

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1736963/publications.pdf>

Version: 2024-02-01

42
papers

519
citations

759055

12
h-index

713332

21
g-index

45
all docs

45
docs citations

45
times ranked

913
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Complete Revascularization on 10-Year Survival of Patients With Stable Multivessel Coronary Artery Disease. <i>Circulation</i> , 2012, 126, S158-63.	1.6	56
2	Impact of diabetes on 10-year outcomes of patients with multivessel coronary artery disease in the Medicine, Angioplasty, or Surgery Study II (MASS II) trial. <i>American Heart Journal</i> , 2013, 166, 250-257.	1.2	54
3	Troponin in diabetic patients with and without chronic coronary artery disease. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 72.	0.7	34
4	Clinical significance of chronic myocardial ischemia in coronary artery disease patients. <i>Journal of Thoracic Disease</i> , 2019, 11, 1005-1015.	0.6	34
5	Cost-Effectiveness Analysis for Surgical, Angioplasty, or Medical Therapeutics for Coronary Artery Disease. <i>Circulation</i> , 2012, 126, S145-50.	1.6	33
6	Effect of Hypoglycemic Agents on Ischemic Preconditioning in Patients With Type 2 Diabetes and Symptomatic Coronary Artery Disease. <i>Diabetes Care</i> , 2013, 36, 1654-1659.	4.3	29
7	Cancer-related deaths among different treatment options in chronic coronary artery disease. <i>Coronary Artery Disease</i> , 2012, 23, 79-84.	0.3	24
8	Association Between Stress Testingâ€“Induced Myocardial Ischemia and Clinical Events in Patients With Multivessel Coronary Artery Disease. <i>JAMA Internal Medicine</i> , 2019, 179, 1345.	2.6	24
9	Accuracy of Myocardial Biomarkers in the Diagnosis of Myocardial Infarction After Revascularization as Assessed by Cardiac Resonance: The Medicine, Angioplasty, Surgery Study V (MASS-V) Trial. <i>Annals of Thoracic Surgery</i> , 2016, 101, 2202-2208.	0.7	20
10	Type 2 diabetes mellitus and myocardial ischemic preconditioning in symptomatic coronary artery disease patients. <i>Cardiovascular Diabetology</i> , 2015, 14, 66.	2.7	17
11	Long-term analysis of left ventricular ejection fraction in patients with stable multivessel coronary disease undergoing medicine, angioplasty or surgery: 10-year follow-up of the MASS II trial. <i>European Heart Journal</i> , 2013, 34, 3370-3377.	1.0	16
12	Impact of Chronic Kidney Disease on Long-Term Outcomes in Type 2 Diabetic Patients With Coronary Artery Disease on Surgical, Angioplasty, or Medical Treatment. <i>Annals of Thoracic Surgery</i> , 2016, 101, 1735-1744.	0.7	16
13	Association of Longitudinal Values of Glycated Hemoglobin With Cardiovascular Events in Patients With Type 2 Diabetes and Multivessel Coronary Artery Disease. <i>JAMA Network Open</i> , 2020, 3, e1919666.	2.8	14
14	Long-term outcomes of patients with stable coronary disease and chronic kidney dysfunction: 10-year follow-up of the Medicine, Angioplasty, or Surgery Study II Trial. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1369-1376.	0.4	13
15	Ten-year outcomes of patients randomized to surgery, angioplasty, or medical treatment for stable multivessel coronary disease: Effect of age in the Medicine, Angioplasty, or Surgery Study II trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 146, 1105-1112.	0.4	12
16	Ten-Year Follow-Up of Off-Pump and On-Pump Multivessel Coronary Artery Bypass Grafting: MASS III. <i>Angiology</i> , 2019, 70, 337-344.	0.8	11
17	Impact of hypoglycemic agents on myocardial ischemic preconditioning. <i>World Journal of Diabetes</i> , 2014, 5, 258.	1.3	11
18	Hypotheses, rationale, design, and methods for prognostic evaluation of cardiac biomarker elevation after percutaneous and surgical revascularization in the absence of manifest myocardial infarction. A comparative analysis of biomarkers and cardiac magnetic resonance. The MASS-V Trial. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 65.	0.7	10

#	ARTICLE	IF	CITATIONS
19	Comparative cost-effectiveness of surgery, angioplasty, or medical therapy in patients with multivessel coronary artery disease: MASS II trial. <i>Cost Effectiveness and Resource Allocation</i> , 2018, 16, 55.	0.6	10
20	Comparison between off-pump and on-pump coronary artery bypass grafting in patients with severe lesions at the circumflex artery territory: 5-year follow-up of the MASS III trial. <i>European Journal of Cardio-thoracic Surgery</i> , 2015, 47, 455-458.	0.6	7
21	On-pump versus off-pump coronary artery bypass surgery in patients older than 60 years: five-year follow-up of MASS III trial. <i>Journal of Cardiothoracic Surgery</i> , 2014, 9, 127.	0.4	5
22	The cost-effectiveness of strategies in coronary artery disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 805-813.	0.7	5
23	Biomarker release after percutaneous coronary intervention in patients without established myocardial infarction as assessed by cardiac magnetic resonance with late gadolinium enhancement. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 87-93.	0.7	5
24	Myocardial injury in diabetic patients with multivessel coronary artery disease after revascularization interventions. <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 92.	1.2	5
25	Cost-effectiveness of on-pump and off-pump coronary artery bypass grafting for patients with coronary artery disease: Results from the MASS III trial. <i>International Journal of Cardiology</i> , 2018, 273, 63-68.	0.8	5
26	Hypotheses, rationale, design, and methods for evaluation of ischemic preconditioning assessed by sequential exercise tests in diabetic and non-diabetic patients with stable coronary artery disease – a prospective study. <i>BMC Cardiovascular Disorders</i> , 2013, 13, 117.	0.7	4
27	Significant elevation of biomarkers of myocardial necrosis after coronary artery bypass grafting without myocardial infarction established assessed by cardiac magnetic resonance. <i>Medicine (United Tj ETQq1 1 0 7 8 4 3 1 4 r g B T / O v e r d o c k 1 0 T f</i>	0.7	4
28	Abnormal elevation of myocardial necrosis biomarkers after coronary artery bypass grafting without established myocardial infarction assessed by cardiac magnetic resonance. <i>Journal of Cardiothoracic Surgery</i> , 2017, 12, 122.	0.4	4
29	Conservative strategy for treatment of stable coronary artery disease. <i>World Journal of Clinical Cases</i> , 2015, 3, 163.	0.3	4
30	Acute myocarditis in H1N1 influenza a virus infection. <i>Revista Da Associação Médica Brasileira</i> , 2010, 56, 394-394.	0.3	4
31	The challenge of treating elderly coronary artery disease patients. <i>Journal of Thoracic Disease</i> , 2016, 8, 1434-1436.	0.6	3
32	Acute inferolateral ST-elevation myopericarditis diagnosed by delayed enhancement cardiac computed tomography. <i>Journal of Cardiology Cases</i> , 2011, 3, e90-e93.	0.2	2
33	A case of mid-apical obstructive hypertrophic cardiomyopathy treated with a transapical myectomy approach: a case report. <i>Journal of Medical Case Reports</i> , 2014, 8, 364.	0.4	2
34	Recurrent Angina Caused by Coronary Subclavian Steal Syndrome Confirmed by Positron Emission Tomography. <i>Annals of Thoracic Surgery</i> , 2015, 99, e111-e114.	0.7	2
35	The Influence of Diabetes Mellitus in Myocardial Ischemic Preconditioning. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-6.	1.0	2
36	Significant association of SYNTAX score on release of cardiac biomarkers in uncomplicated post-revascularization procedures among patients with stable multivessel disease. <i>Medicine (United Tj ETQq0 0 0 0 r g B T / O v e r d o c k 1 0 T f</i>	0.8	2

#	ARTICLE	IF	CITATIONS
37	Hypotheses, rationale, design, and methods for prognostic evaluation of a randomized comparison between patients with coronary artery disease associated with ischemic cardiomyopathy who undergo medical or surgical treatment: MASS-VI (HF). <i>Trials</i> , 2020, 21, 337.	0.7	2
38	Continuous glucose monitoring in obese pregnant women with no hyperglycemia on glucose tolerance test. <i>PLoS ONE</i> , 2021, 16, e0253047.	1.1	2
39	Interventional therapies in ischemic ventricular dysfunction: facts and versions!. <i>Annals of Translational Medicine</i> , 2016, 4, S27-S27.	0.7	2
40	Surgical and percutaneous revascularization outcomes based on SYNTAX I, II, and residual scores: a long-term follow-up study. <i>Journal of Cardiothoracic Surgery</i> , 2021, 16, 248.	0.4	1
41	Stress Testing and Risk Prediction in People With Known Symptomatic Multivessel Coronary Artery Disease—Reply. <i>JAMA Internal Medicine</i> , 2020, 180, 166.	2.6	0
42	Diagnostic Management and Surgical Treatment of Isolated Tricuspid Regurgitation. <i>Case Reports in Cardiology</i> , 2021, 2021, 1-5.	0.1	0